Ved anvendelse af COC i højere doser (50 mikrogram etinylestradiol) reduceres risiko for endometrie - og ovariecancer.
With the use of higher dosed COCs (50 microgram ethinyl estradiol) the risk of endometrial and ovarian cancer is reduced.